Brain Cancer

P1, N=24, Not yet recruiting, Capital Medical University

P1, N=50, Recruiting, University of California, San Francisco | Suspended --> Recruiting

P1/2, N=68, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

P4, N=175, Recruiting, Orszagos Onkologiai Intezet | Not yet recruiting --> Recruiting

Ferroptosis inducers (sorafenib, erastin) heightened LDH release and reduced viability, while inhibitors (ferrostatin-1, U0126) had opposing effects...STXBP1 functions as a tumor suppressor in glioma, regulating ferroptosis and EMT. It shows potential as a therapeutic target in glioma management.

Furthermore, static magnetic fields have been reported to increase apoptosis, inhibit proliferation, and may offer a complementary treatment with low toxicity. These findings suggest that magnetic-field-based approaches offer an innovative strategy for GBM treatment.

Integration with TCGA data identified 10 oncogenic genes (PARP10, OAS1, OAS3, PRR4, ZNFX1, HELZ2, SP110, CSRNP1, DDX3L, and PARP14) dysregulated across 20+ cancer types; qPCR confirmed their consistent downregulation posttreatment in both cell lines (P<0.05). This study establishes parimifasor's antitumor efficacy via the suppression of immune pathway-associated oncogenes, supporting its repurposing as a cancer therapeutic agent and providing biomarker candidates for clinical development.

The observed loss of phagocytic capacity reflects dynamic functional state transitions toward an inflammatory and hypoxic phenotype rather than the passive enrichment of a single subpopulation. These insights provide a single-cell evolutionary framework for metastasis-associated immune reprogramming and underscore the potential of CD74 as a target for therapeutic intervention.

This study identifies HSG as a critical tumor suppressor in malignant meningioma that restrains tumor aggressiveness by dampening the Wnt/β-catenin cascade. These novel findings highlight the HSG-Wnt/β-catenin axis as a promising therapeutic target, offering new translational strategies for the management of this highly aggressive intracranial tumor.

Drug sensitivity analysis revealed differential half-maximal inhibitory concentration (IC50) values for 20 anticancer agents between risk groups. Our findings suggest that SOX21-AS1 may influence the tumor microenvironment through the modulation of the immune checkpoint CD274, potentially serving as a novel prognostic indicator and a target for immunotherapeutic strategies in GBM.

The TMEp phase integrated stereotactic body radiotherapy (SBRT), low-dose etoposide, and anlotinib, followed by CI with the programmed death 1 (PD-1)/cytotoxic T lymphocyte antigen 4 (CTLA-4) bispecific antibody cadonilimab and concurrent probiotic supplementation...The TMEp-CI-M platform may enhance the efficacy of immunotherapy in ES-SCLC, enabling durable responses even in patients with brainstem metastases. Although this platform has demonstrated promise across multiple tumor types, further prospective and mechanistic studies are warranted to confirm its clinical utility.

Despite overlapping pathological features, uterine and gastrointestinal stromal tumors differ clinically. Surgery is the primary treatment; comprehensive preoperative imaging and postoperative pathological examination are critical to prevent misdiagnosis and optimize management.